Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Terumo: New Pump Data Management System
April 8, 2002
- Cancer Detected, Suspected in 38,873 Individuals: Municipal Cancer Examinations
April 8, 2002
- JV for Animal Health by BI, Shionogi, Starts Operation
April 8, 2002
- Terumo Obtains Marketing Rights for Portable Insulin Pump
April 8, 2002
- Sleep Disorders Discussed: Fujisawa, Sanofi-Synthelabo Seminar
April 8, 2002
- Korosho Announces New Research Projects for FY2002
April 8, 2002
- Yamanouchi to Nearly Achieve 6% Market Share: President Takenaka
April 8, 2002
- FY2002 Budget Approved by Diet
April 8, 2002
- Takeda Subscribes to Gene Logic's Gene Expression Database
April 8, 2002
- REGULATORY NEWS IN BRIEF
April 8, 2002
- Sankyo Transfers Development of Glaucoma Drug to Santen
April 8, 2002
- Elimination of Prescription Period Limitation Should Help Bungyo : Expert
April 8, 2002
- Nippon Shinyaku to Market HIGA Mice via Japan SLC
April 8, 2002
- Final Draft GL for Acute Pancreatitis Presented by JSAEM
April 8, 2002
- Otsuka, Otsuka Pharm Factory, Snow Brand Milk Create JV for Clinical Nutrition
April 8, 2002
- Korosho to Construct Critical Path-Sharing System
April 8, 2002
- Major Maker's New Invoice Prices Are More Acceptable than Before: Suzuken
April 8, 2002
- Doctors' Participation in Clinical Trial Training Disappointing
April 8, 2002
- BUSINESS NEWS IN BRIEF
April 8, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 8, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…